Unveiling the Shadows: New Frontier in Cancer Biology
Cancer research is continually evolving, branching into areas previously unexplored or deemed less significant. A prime example of this evolution is the study of pseudogenes and their impact on cancer, specifically esophageal carcinoma. How do the Pseudogenes Drive Cancer Progression in the Oesophagus? Pseudogenes are DNA sequences that resemble functional genes but have lost their ability to produce proteins. Conventionally regarded as genomic fossils without functional roles, pseudogenes have emerged as pivotal players in cellular differentiation, development, and cancer pathogenesis. This transformative insight into pseudogenes role in esophageal carcinoma marks a new frontier in understanding cancer’s molecular underpinnings and potential therapeutic targets.
Role of Pseudogenes: Beyond Junk DNA
Pseudogenes, once considered mere remnants of evolution, have been implicated in regulating cellular differentiation and organismal development. Their involvement in cancer-associated differentiation, particularly in esophageal carcinoma, has opened new avenues for research. By exploring the tumor landscape of esophageal carcinoma, researchers have identified pseudogenes that regulate differentiation events promoting oncogenic transformation. This astonishing work not only challenges the notion of pseudogenes as junk DNA but also highlights their significance in cancer biology.
A recent study has shown that pseudogenes can still regulate gene expression and cellular functions through various mechanisms. In the new study published in BMC Genomics, ‘Stage II oesophageal carcinoma: peril in disguise associated with cellular reprogramming and oncogenesis regulated by pseudogenes’, the researchers Dr. Govada Pravallika and Dr. Ramalingam Rajasekaran explored the role of pseudogenes in oesophageal carcinoma, a type of cancer that affects the tube that connects the mouth to the stomach.
Dangers of Stage II Oesophageal Carcinoma
Oesophageal carcinoma (ESCA) is the eighth most common cancer and the sixth most common cause of cancer-related deaths worldwide. ESCA can be classified into four stages based on the extent of tumour invasion and spread. Stage I and II are considered early stages, while stage III and IV are advanced stages. However, the researchers found that stage II ESCA (SII) has a unique molecular profile that makes it more prone to cellular reprogramming and oncogenic transformation than other stages.
Using gene expression data from 151 ESCA patients, the researchers identified 45 pseudogenes that are associated with cellular differentiation, a process that determines the fate and function of cells. They found that these pseudogenes have different expression patterns across the stages of ESCA, with SII having the highest number of upregulated pseudogenes. They also found that these pseudogenes interact with other genes that are involved in development, stem cell maintenance, and cancer progression.
The researchers performed gene set enrichment analysis (GSEA) to identify the biological pathways and processes that are affected by the pseudogenes and their interacting genes. They found that SII ESCA has a high degree of differentiation, meaning that it resembles the cells of other tissues in the gastrointestinal tract, such as the stomach and the intestine. This suggests that SII ESCA undergoes a process of transdifferentiation, where one cell type converts into another, or transcommitment, where a stem cell changes its lineage.
The researchers also constructed gene regulatory networks (GRNs) to visualize the interactions and influences among the pseudogenes and their interacting genes. They found that SII ESCA has a highly robust and pleiotropic GRN, meaning that it can withstand perturbations and affect multiple biological outcomes. They identified several key transcription factors and microRNAs that mediate the effects of pseudogenes on cellular reprogramming and oncogenesis in SII ESCA. For example, they found that SOX2, a master regulator of stem cell potential, is regulated by pseudogenes and in turn regulates other pseudogenes and genes involved in cancer.
Implications of Pseudogene Expression
The researchers further stratified the SII ESCA patients based on the expression pattern of pseudogenes and performed mutation analysis and survival analysis. They found that the patients with a high expression of both upregulated and downregulated pseudogenes have a distinct mutational landscape and a poor prognosis compared to the patients with a low expression of both types of pseudogenes. They also found that the patients with a high expression of both types of pseudogenes have a high level of APOBEC3A, an enzyme that induces DNA mutations, and a low level of APOBEC3G, an enzyme that inhibits viral replication. This suggests that the pseudogene expression may affect the balance between mutagenesis and antiviral defense in SII ESCA.
Pravallika and Rajasekharan concluded that pseudogenes associated with cellular differentiation may play a crucial role in initiating cellular reprogramming and facilitating oncogenic transformation, especially in SII ESCA. They also proposed that pseudogenes may serve as unconventional biomarkers for diagnosis, prognosis, and therapy of ESCA. They suggested that further studies are needed to validate their findings and to explore the mechanisms and functions of pseudogenes in ESCA and other cancers.
Click to know More from Govada Pravallika
Deciphering the Pseudogene-Cancer Nexus
The investigation into pseudogenes role in esophageal carcinoma employed cutting-edge methodologies, including DESeq2 for gene expression analysis, ‘InteractiVenn’ for expression pattern identification, and various bioinformatics tools for gene regulatory network construction. Through these techniques, researchers uncovered the unique stage-wise expression patterns of pseudogenes in esophageal carcinoma, revealing their critical role in cellular reprogramming and oncogenesis.
The study provides compelling evidence of pseudogenes’ involvement in regulating key processes in stage II esophageal carcinoma, such as cellular reprogramming and differentiation. By affecting the expression of significant oncogenes and transcription factors, pseudogenes contribute to the complexity of the cancer phenotype. This intricate relationship underscores the potential of pseudogenes as biomarkers for early diagnosis and therapeutic targets.
The revelation of pseudogenes’ role in esophageal carcinoma opens new therapeutic possibilities. Understanding how pseudogenes regulate cancer-associated differentiation and contribute to oncogenesis paves the way for innovative treatments. Targeting pseudogene-regulated pathways could offer novel strategies for combating esophageal carcinoma, highlighting the need for further research in this promising area.
A Paradigm Shift in Cancer Research
The study by Pravallika and Rajasekharan of pseudogenes in esophageal carcinoma represents a paradigm shift in cancer research, challenging long-held beliefs and opening new research and therapeutic avenues. By shedding light on the functional importance of pseudogenes, this research not only enhances our understanding of cancer biology but also provides hope for more effective treatments in the future.
For the full research article click the link
– NSH Digi Desk
